The PEGASUS trial [14] was a 48-week, multicentre, international, randomised, open-label, active-comparator, phase III RCT designed to assess the clinical effectiveness of pegcetacoplan at the licensed dose (1080 mg self-administered subcutaneously [SC] twice weekly or every 3 days) compared with patients’ current prescribed eculizumab dosage (intravenous [IV] infusion; range: 900–1500 mg every 2 weeks) for patients with PNH whose anaemia was not controlled after treatment with a C5 inhibitor. Here, C5 is linked to anemia.